Jaypirca Pirtobrutinib Reversible BTK Inhibitor CLL MCL Review 2026
Author: Critical Kare PharmaLymphoma & Leukemia Desk
On October 25, 2026, hematologic oncology societies highlighted Jaypirca® (Pirtobrutinib 100 mg and 50 mg film-coated tablets) by Eli Lilly as the first approved non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor.
Unlike covalent inhibitors (ibrutinib, acalabrutinib, zanubrutinib) that require binding to Cys481, Jaypirca binds BTK non-covalently, restoring disease control in patients who have progressed on prior covalent BTK inhibitors due to BTK C481S resistance mutations.
Through Critical Kare Pharma, certified genuine packs of Jaypirca Pirtobrutinib Tablets are supplied directly to hematology departments and named patients globally.
The BRUIN Landmark Clinical Benchmarks
- CLL/SLL Cohort: Confirmed 82.2% overall response rate in patients with relapsed/refractory CLL previously treated with both covalent BTK inhibitors and BCL-2 inhibitors (venetoclax).
- Mantle Cell Lymphoma: Demonstrated an overall response rate of 57.8% with durable remissions in relapsed/refractory MCL.
- Dosing: Recommended dose is 200 mg orally once daily, swallowed whole with water.
Global Sourcing via Critical Kare Pharma
Supplied in original manufacturer packaging with verifiable Certificates of Analysis under international personal import regulations.
